Published

January 27, 2026

Obecabtagene autoleucel [OBE01b]

Obecabtagene autoleucel (obecel) for treating relapsed/refractory Philadelphia negative and positive B cell acute lymphoblastic leukaemia in patients aged 26 years and older where the following criteria have been met: This second form is to document the date of infusion of CAR T cell therapy and for registration of this infusion with NHS England so that the treating Trust is reimbursed for the cost of obecabtagene autoleucel (obecel). There is a first form for the approval of leucapheresis and manufacture of CAR T cells. This second form must use the same unique Blueteq identifier number generated when this patient was registered for leucapheresis and CAR T cell manufacture using the first form.

  1. This application is being made by and treatment with obecabtagene autoleucel (obecel) will be initiated by a consultant haematologist specifically trained and accredited in the use of systemic anti-cancer therapy and working in an accredited CAR-T cell treatment centre and who is a member of the National CAR T Clinical Panel for adult acute lymphoblastic leukaemia and a member of the treating Trust’s adult acute lymphoblastic leukaemia and CAR-T cell multidisciplinary teams.
  2. The patient was either treated with bridging therapy in between leucapheresis and CAR-T cell infusion or not. Please indicate what type(s) of bridging therapy have been required by ticking the most appropriate option below:
  • no bridging therapy at all or
  • Corticosteroids only or
  • TKI therapy with or without steroids or
  • systemic cytotoxic chemotherapy with or without steroids or
  • systemic cytotoxic chemotherapy plus TKI with or without steroids or
  • inotuzumab with or without steroids or
  • other
  1. The patient has an ECOG performance status of 0 or 1. Please mark in the box below the current performance status:
  • PS 0 or
  • PS 1
  1. The patient has sufficient end organ function to tolerate treatment with obecabtagene autoleucel (obecel).
  2. Obecabtagene autoleucel (obecel) will be used as set out in its Summary of Product Characteristics (SPC).
  3. Following national approval for use of obecabtagene autoleucel (obecel) there has been local CAR T cell multidisciplinary team agreement that this patient continues to have the necessary fitness for treatment and fulfils all the treatment criteria listed here.

CDF funded From: 25 November 2025

Form version: -

CDF Managed Access: No

NICE Technology Appraisal: NA (NA)

Current Form Version

Note

The data on this page was produced using version 1.385 of the CDF list, downloaded from NHS England’s website on 27 January 2026 at 22:25.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.

Citation

BibTeX citation:
@misc{untitled,
  author = {},
  title = {\textless\textless\textless FULL
    {TITLE\textgreater\textgreater\textgreater{}}},
  number = {\textless\textless\textless FORM
    ID\textgreater\textgreater\textgreater{}},
  date = {},
  url = {https://updates.chemo.org.uk/CDF_Forms/OBE01b.html},
  langid = {en}
}
For attribution, please cite this work as:
<<<FULL TITLE>>>. Chemotherapy Updates. https://updates.chemo.org.uk/CDF_Forms/OBE01b.html